Corrected versus total body weight for dosage of sugammadex in morbidly obese patients. A randomized, double-blind, controlled trial

Minerva Anestesiol. 2021 Mar;87(3):371-373. doi: 10.23736/S0375-9393.20.15038-7. Epub 2020 Dec 16.

Authors

Michele Carron¹, Giovanna Ieppariello², Alessandro DE Cassai², Chiara Lambertini², Federico Linassi², Paolo Navalesi²

Affiliations

¹ Section of Anesthesiology and Intensive Care, Department of Medicine DIMED, University of Padua, Padua, Italy - michele.carron@unipd.it.
² Section of Anesthesiology and Intensive Care, Department of Medicine DIMED, University of Padua, Padua, Italy.

PMID: 33325220
DOI: 10.23736/S0375-9393.20.15038-7

No abstract available

Publication types

Randomized Controlled Trial

MeSH terms

Body Weight
Double-Blind Method
Humans
Neuromuscular Nondepolarizing Agents*
Obesity, Morbid* / complications
Sugammadex
gamma-Cyclodextrins*

Substances

Neuromuscular Nondepolarizing Agents
gamma-Cyclodextrins
Sugammadex